Status:
UNKNOWN
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
Lead Sponsor:
Centers for Disease Control and Prevention, China
Conditions:
Safety
Immunogenicity, Vaccine
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent...
Eligibility Criteria
Inclusion
- Healthy adults 18 years old and older
- Over 6 months after primary immunization with COVID-19 vaccines
- Can understand and sign the consent
- Can provide effective personal identification
Exclusion
- Has a history of COVID-19 infection
- Less than 6 months after primary immunization with COVID-19 vaccines
- Already vaccinated with influenza vaccines of that year
- Vaccinated with pneumococcal vaccines within 5 years
- Has a history of severe hypersensitivity reaction to vaccines
- Has uncontrolled seizure or other severe neural system illnesses
- Has a fever, chronic disease, or acute disease during immunization
- Gestation period, lactation period, or planning to get pregnant within 3 months
- Administrated with other drugs under research within 30 days before vaccination
- Received attenuated vaccines within 14 days before vaccination
- Received subunit vaccines or inactivated vaccines within 7 days before vaccination
- Other conditions based on researcher's judgement
Key Trial Info
Start Date :
October 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT05298800
Start Date
October 8 2021
End Date
December 31 2023
Last Update
March 28 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Daxing District Center of Disease Control and Prevention
Beijing, China
2
Huairou District Center of Disease Control and Prevention
Beijing, China
3
Miyun District Center of Disease Control and Prevention
Beijing, China